The administration of guanidine in amyotrophic lateral sclerosis.
D000328:Adult; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000503:physiopathology; D001259:Ataxia / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006146:Guanidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000503:physiopathology; D009325:Nausea / Q000139:chemically induced; D010243:Paralysis / Q000139:chemically induced; D012129:Respiratory Function Tests; D014717:Vertigo / Q000139:chemically induced; D014797:Vital Capacity
D006146:Guanidines